PMCB (PharmaCyte Biotech) Net Margin %: 0.00% (As of Jan. 2026)


PMCB PharmaCyte Biotech Inc PMCB
32 GF Score
Price $0.76
! 2 Warning Signs
View Full Analysis

What is PharmaCyte Biotech Net Margin %?

PharmaCyte Biotech PMCB -0.30% 32 Net Margin % is 0.00% as of Jan. 2026. GuruFocus rates PMCB with a GF Score™ of 32/100. The stock has 2 warning signs investors should review. Among 947 Biotechnology companies, PharmaCyte Biotech ranks worse than 105596.52% on this metric.

Net margin is calculated as Net Income divided by its Revenue. PharmaCyte Biotech's Net Income for the three months ended in Jan. 2026 was $0.75 Mil. PharmaCyte Biotech's Revenue for the three months ended in Jan. 2026 was $0.00 Mil. Therefore, PharmaCyte Biotech's net margin for the quarter that ended in Jan. 2026 was 0.00%.

The historical rank and industry rank for PharmaCyte Biotech's Net Margin % or its related term are showing as below:


PMCB's Net Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -89.33
* Ranked among companies with meaningful Net Margin % only.

PharmaCyte Biotech  (NAS:PMCB) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

PharmaCyte Biotech Net Margin % Related Terms

PharmaCyte Biotech Net Margin % Historical Data

* Premium members only.

The historical data trend for PharmaCyte Biotech's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

PharmaCyte Biotech Net Margin % Chart

PharmaCyte Biotech Annual Data
Trend Apr16 Apr17 Apr18 Apr19 Apr20 Apr21 Apr22 Apr23 Apr24 Apr25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PharmaCyte Biotech Quarterly Data
Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PMCB vs IMNN, ACXP, ENVB: Net Margin % Comparison

For the Biotechnology subindustry, PharmaCyte Biotech's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

PharmaCyte Biotech Net Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PharmaCyte Biotech's Net Margin % distribution charts can be found below:

* The bar in red indicates where PharmaCyte Biotech's Net Margin % falls into.


PMCB
32GF Score
PharmaCyte Biotech Inc PMCB
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

PharmaCyte Biotech Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

PharmaCyte Biotech's Net Margin for the fiscal year that ended in Apr. 2025 is calculated as

Net Margin=Net Income (A: Apr. 2025 )/Revenue (A: Apr. 2025 )
=30.656/0
= %

PharmaCyte Biotech's Net Margin for the quarter that ended in Jan. 2026 is calculated as

Net Margin=Net Income (Q: Jan. 2026 )/Revenue (Q: Jan. 2026 )
=0.747/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of 0.00% mean?
PharmaCyte Biotech (PMCB) has a Net Margin % of 0.00% as of Jan. 2026. Net margin is the ratio of total net income to net sales. View historical data on PharmaCyte Biotech and its competitors. According to the industry distribution chart, PharmaCyte Biotech ranks #999999 out of 947 companies in the Biotechnology industry.
Is PharmaCyte Biotech's Net Margin % too high?
PharmaCyte Biotech's current Net Margin % is 0.00%. Based on the distribution chart, PharmaCyte Biotech ranks #999999 out of 947 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, PharmaCyte Biotech has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does PharmaCyte Biotech's Net Margin % compare to IMNN and ACXP?
According to the Biotechnology industry distribution chart, PharmaCyte Biotech ranks #999999 out of 947 companies for Net Margin %. This places PharmaCyte Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on PharmaCyte Biotech and its competitors. PharmaCyte Biotech's current Net Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCyte Biotech stock overvalued right now?
PharmaCyte Biotech (PMCB) has a current Net Margin % of 0.00%. The current Net Margin % is 0.00%. PharmaCyte Biotech's overall GF Score™ is 32/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For PharmaCyte Biotech (PMCB), the current Net Margin % is 0.00% as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

PharmaCyte Biotech Business Description

Address 3960 Howard Hughes Parkway, Suite 500, Las Vegas, NV, USA, 89169
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
32GF Score

Get the complete analysis for PMCB

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.76
Price